Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Momenta Continues Its Transition

TheMotleyFool

0 0

Momenta Pharmaceuticals (NASDAQ: MNTA) continues its transition from a drugmaker specializing in hard-to-make generic drugs to one focused on novel products. The financial numbers aren't going to be pretty during the transition, so investors should focus on the pipeline.

Fortunately, with $380 million in the bank, Momenta has a solid runway to get to at least proof of concept for its novel products.

Metric

Quelle Fool.com

Like: 0

MNTA

Share